Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sf2aWC
- Development stage
- Phase 2
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Sf2aWC is a formalin-inactivated, whole-cell oral vaccine candidate designed to prevent shigellosis caused by *Shigella flexneri* 2a. Originally developed by the Walter Reed Army Institute for Research (WRAIR) and currently being advanced by PATH, the vaccine targets the lipopolysaccharide (LPS) antigen on the bacterial surface. It is designed to induce mucosal and systemic immunity, including anti-LPS antibodies in serum and feces. Clinical evaluation includes testing the vaccine alone or in combination with the double mutant *E. coli* heat-labile toxin (dmLT) adjuvant to enhance immunogenicity and protective efficacy against gastrointestinal infection.
- Other names
- Shigella flexneri 2a whole cell vaccineInactivated Shigella flexneri 2a whole cell vaccineSf2aWC vaccineSf-2aWC vaccineSf 2aWC vaccineSf2aWC-PATH-shigellosisSf-2aWC-PATH-shigellosisSf 2aWC-PATH-shigellosis
02
Targets
IpaD (Invasion plasmid antigen D)IpaB (Invasion plasmid antigen B)
Beyond the preview
Go deeper on Sf2aWC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sf2aWC.